MHRA has confirmed that its GOV.UK guidance on clinical-trial safety-event collection, verification and reporting should now be treated as effective (rather than draft) because the amended UK Clinical Trials Regulations took full effect on 28 April 2026.
For pharmacovigilance and clinical safety teams supporting investigational medicinal product (IMP) trials in the United Kingdom, the practical impact is immediate: processes and documentation that were previously aligned to “draft-era” guidance may need to be reassessed and, where appropriate, updated to reflect the guidance’s effective status as of 28 April 2026.
MHRA’s guidance page “Clinical trials for medicines: collection, verification and reporting of safety events” shows it was published on 25 June 2025 and last updated on 28 April 2026. On that page, MHRA states that the amended Clinical Trials Regulations took full effect on 28 April 2026 and, as a result, the guidance should now be considered effective.
The contents list on the safety-events guidance page indicates the operational scope that PV and clinical operations teams should expect to map into controlled procedures. The listed topics include MedDRA coding; reporting adverse events (AEs) and serious adverse events (SAEs); reference safety information (RSI); reporting suspected unexpected serious adverse reactions (SUSARs); annual safety reporting; urgent safety measures (USMs); serious breaches; and temporarily suspending a trial.
In parallel, MHRA’s “Medicines: clinical trials hub” page also reflects that the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 came into force on 28 April 2026 and that the hub page was last updated on 28 April 2026. Taken together, these updates support a clear interpretation for compliance planning: MHRA’s clinical-trial safety-event reporting framework is no longer positioned as draft guidance and is explicitly described as effective.
What PV teams should do next is therefore less about interpreting new technical requirements (the available excerpts do not provide detailed procedural rules such as submission timelines or formats) and more about governance, traceability, and inspection readiness. Organizations should be able to demonstrate that their UK trial safety-event workflow documentation, training assignments, and execution evidence align with the now-effective MHRA guidance areas.
From a workflow perspective, this update touches individual case safety report (ICSR) handling in the clinical-trial setting (including SUSAR processing and reporting), country compliance controls specific to the United Kingdom, inspection readiness expectations (e.g., controlled documentation and audit trails), and CAPA management where gaps are identified.
Affected stakeholders typically include the Local Safety Officer responsible for country-specific trial safety obligations, the PV Operations Lead overseeing safety case operations and reporting, the PV Quality Lead ensuring controlled documentation and training compliance, the Regulatory Intelligence Lead tracking regulator communications and operationalizing changes, and the Medical Safety Physician supporting medical review and governance decisions (e.g., around RSI and safety reporting judgments).
Organizations with active UK IMP trials or UK trials onboarding after 28 April 2026 should consider a documented gap assessment against MHRA’s effective guidance sections. Where changes are needed, controlled SOPs and work instructions should be updated and staff training records should be refreshed to reflect the guidance’s effective status as of 28 April 2026. Any identified deviations or gaps should be documented and addressed through CAPA as appropriate.
Teams may also wish to set monitoring for MHRA updates using the GOV.UK page email alert feature referenced in the action card, to ensure subsequent changes to the guidance are captured and assessed in a timely manner.
Practical implication: For UK IMP trials active or onboarding post-28 April 2026, run and document a UK clinical-trial safety reporting gap assessment against MHRA’s now-effective guidance topics (MedDRA coding; AE/SAE reporting; RSI governance; SUSAR reporting; annual safety reporting; urgent safety measures; serious breaches; temporary suspension), then update controlled procedures and training and open CAPA for any gaps identified.
